Sulfato de abacavir-lamivudina<br> VIH
Levocetirizina<br> Alergía
Atovacuona/Proguanil<br> Antiinfecciosos
Propionato de fluticasona<br> Respiratorio
Ceftazidima<br> Antiinfecciosos
Naratriptán<br> Sistema Nervioso Central
Cetirizina dihidrocloruro<br> Alergía
Lamivudina-Zidovudina<br> VIH
Salmeterol<br> Respiratorio
Al acceder a esta sesión encontrará toda la información sobre Anoro Ellipta y el desafio "Inicie con fuerza
Al acceder a esta sesión encontrará toda la información sobre Anoro Ellipta y el desafio "Inicie con fuerza
Published data showing that Relvar has a lower annual carbon footprint and lower lifecycle contributions than many other asthma devices.
Real-world data showing that Relvar new users were more adherent to, and less likely to discontinue, treatment than new users of other ICS/LABA combinations.
A patient case study illustrates how Relvar can address invisible symptoms vs patient perceptions of asthma control with ICS/LABA MART regimens.
Patient case studies showing how patient perceptions of asthma control differ from guideline definitions.
How Relvar can achieve asthma control, using guideline definitions and ACT assessment (includes an external link to the ACT website).
The maximum licensed dose of Relvar does not affect the HPA axis or significantly suppress cortisol levels.
Relvar’s particle size falls well within the optimal range for absorption, a factor in asthma control that is often overlooked.
Relvar efficacy data from the SLS, which included patients with comorbidities and those who were smokers, who would usually be excluded from RCTs.
Post-hoc analysis night-time awakening data from three RCTs and AQLQ data showing how patients with uncontrolled asthma can benefit from taking Relvar.
Real-world evidence and clinical trial data reveal how Relvar can reduce the rate of asthma exacerbations vs budesonide/formoterol and ICS, respectively.
GINA guidelines state that SABA use > twice weekly suggests poor asthma control. Real-world data vs budesonide/formoterol show how Relvar reduces SABA dependence.
Key Relvar benefits in adults/adolescents with uncontrolled, partially controlled or adequately controlled asthma.
Exclusively created for healthcare professionals to provide information, services and support related to VOCABRIA▼ (cabotegravir) + REKAMBYS▼ (rilpivirine)
Exclusively created for healthcare professionals to provide information, services and support related to VOCABRIA▼ (cabotegravir) + REKAMBYS▼ (rilpivirine)
Exclusively created for healthcare professionals to provide information, services and support related to VOCABRIA▼ (cabotegravir) + REKAMBYS▼ (rilpivirine)
Seguridad y tolerabilidad e interacciones farmacológicas
Diseño del estudio ATLAS-2M
Resultados reportados por los pacientes en ATLAS-2M
Ambrisentan<br> Enfermedades Raras
This page contains an overview of Early protection of Rotavirus disease
This page contains an overview of Broad protection of Rotarix vaccination and impact data
This page contains information about safety
This page contains an overview of compliance and coverage of Rotarix vaccine
This page contains an overview of the Rotavirus disease
This page contains parent support materials
Relvar Ellipta’s ease of use is shown by a video and by data vs Breezehaler, while its preference by patients vs Turbohaler, Diskus, and MDI is highlighted.
Seguridad y tolerabilidad
Consideraciones de prescripción e interacciones farmacológicas importantes
Perfil de seguridad general
Seguridad y tolerabilidad de SOLAR
Relvar Ellipta’s ease of use is shown by a video and by data vs Breezehaler, while its preference by patients vs Turbohaler, Diskus, and MDI is highlighted.
Meeting in a Box: Estudio APPaRENT
Data showing that Relvar’s unique formulation provides continuous improvements in lung function and anti-inflammatory effects over the 24-h dosing interval.
A video explanation of therapeutic index and how Relvar’s good therapeutic index is linked to the high receptor binding affinity of its constituent molecules.